KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Elanco Animal Health (ELAN) Shares Outstanding (Diluted Average) (2017 - 2025)

Elanco Animal Health's Shares Outstanding (Diluted Average) history spans 9 years, with the latest figure at $496.4 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) changed 0.18% year-over-year to $496.4 million; the TTM value through Dec 2025 reached $496.4 million, changed 0.18%, while the annual FY2025 figure was $496.4 million, 0.18% changed from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $496.4 million at Elanco Animal Health, down from $501.2 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $501.2 million in Q3 2025 and bottomed at $486.7 million in Q1 2021.
  • The 5-year median for Shares Outstanding (Diluted Average) is $492.7 million (2023), against an average of $492.9 million.
  • The largest annual shift saw Shares Outstanding (Diluted Average) increased 20.5% in 2021 before it decreased 0.18% in 2025.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $487.2 million in 2021, then rose by 0.23% to $488.3 million in 2022, then increased by 0.82% to $492.3 million in 2023, then rose by 1.02% to $497.3 million in 2024, then fell by 0.18% to $496.4 million in 2025.
  • Per Business Quant, the three most recent readings for ELAN's Shares Outstanding (Diluted Average) are $496.4 million (Q4 2025), $501.2 million (Q3 2025), and $499.6 million (Q2 2025).